Publications in collaboration with researchers from Universitat Autònoma de Barcelona (5)

2025

  1. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

    Journal of Clinical Oncology, Vol. 43, Núm. 3, pp. 260-272

  2. Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

    Journal of Clinical Oncology, Vol. 43, Núm. 10, pp. 1254-1265

2024

  1. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

    Annals of Oncology, Vol. 35, Núm. 9, pp. 805-816

  2. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

2011

  1. Brain metastases from lung cancer responding to erlotinib: The importance of EGFR mutation

    European Respiratory Journal, Vol. 37, Núm. 3, pp. 624-631